Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ocugen, Inc. - Common Stock (NQ:OCGN)

0.6946 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocugen, Inc. - Common Stock

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
34 35 Next >
Battle of the COVID Vaccine Contenders: Inovio vs. Ocugen
Both vaccine makers still have big hurdles to jump. 
Via The Motley Fool
Exposures COVID-19
Ocugen Stock: Bull vs. Bear
There's more to this potential coronavirus vaccine stock than what happens in the next 12 months. 
Via The Motley Fool
Exposures COVID-19
Why Ocugen Shot 8% Higher on Friday
There was some highly encouraging news about coronavirus vaccines, but not the one the company is associated with. 
Via The Motley Fool
Exposures COVID-19
The Slide in Ocugen Could Be a Slide to a Homerun
Ocugen has potential for its gene therapy treatment for eye diseases, but OCGN stock movement has been all about Covaxin. 
Via InvestorPlace
Why This Meme Stock Isn't Worth the Trouble
This biotech is targeting a lucrative market, but it may be too late for the company. 
Via The Motley Fool
3 Biotech Stocks That Have More Than Tripled so far This Year
But can they keep up the momentum? 
Via The Motley Fool
2 More Stocks Set to 2x… 5x… 10x in 2022
Finding 10x stocks is possible; it's simply a matter of knowing what patterns to look for. Here are a couple of strong contenders. 
Via InvestorPlace
Topics Economy
Exposures Interest Rates
3 Things About Ocugen That Smart Investors Know
Revenue may not be right around the corner. 
Via The Motley Fool
Exposures COVID-19
Ocugen Proves Groupthink Is a Double-Edged Sword
While OCGN stock is an intriguing idea on the science, when the masses have a different framework, it becomes a risky proposition. 
Via InvestorPlace
Ocugen Needs More Than Covaxin to Boost Its Falling Shares
A doomed-looking vaccine partnership puts Ocugen back in the business of obscurity and OCGN stock at risk of much lower prices. 
Via InvestorPlace
As OCGN Stock Trudges Along Without Real Hope Must Wane
Ocugen is nothing but false hope despite positive news 
Via InvestorPlace
Here's What Needs to Happen for Ocugen Stock to Be a Screaming Buy
The company needs clear regulatory wins in the U.S. and Canada. 
Via The Motley Fool
Is Ocugen About to Beat Moderna in This One Market?
Ocugen aims to be among the first to carve out market share. 
Via The Motley Fool
Exposures COVID-19
WHO’s Nod Can’t Mask Ocugen’s Flimsy Fundamentals
Ocugen has been trying to commercialize a Covid-19 vaccine. However, it's facing many obstacles. Meanwhile, insiders are dumping OCGN stock. 
Via InvestorPlace
Exposures COVID-19
7 Stocks To Sell Before They Head to The Market Graveyard
So, which ones are stocks to sell ASAP? With these seven stocks, all former favorites on both Main Street and Wall Street, consider it high time to take the money and run. 
Via InvestorPlace
Does Ocugen Have a Shot at Winning EUA for Its COVID Vaccine in Kids?
Yes -- but the odds don't look great. 
Via The Motley Fool
Exposures COVID-19
Ocugen, Inc. (OCGN) Q3 2021 Earnings Call Transcript
OCGN earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
OCGN Stock Alert: The Earnings News That Has Ocugen Slipping Today
OCGN stock is pulling back after a muted earnings report this morning, as Ocugen makes a big bet on Covaxin for kids. 
Via InvestorPlace
7 Meme Stocks Ready to Regain Their Lost Momentum
Aggressive investors looking to profit off of the recent impressive volatility in certain companies may want to consider these meme stocks. 
Via InvestorPlace
2 Moonshots That Insiders Are Buying… and 3 They’re Not
The first several days of November saw insiders spend nearly $750 million buying up shares of their companies, which is worth your attention. 
Via InvestorPlace
Sell-the-News Moment Is Your Chance to Reload on Ocugen
Even as OCGN stock moves backward, Ocugen's moving forward with a crucial approval 
Via InvestorPlace
Where Will Ocugen Be in 3 Years?
Most likely in the doldrums, but it could be temporary. 
Via The Motley Fool
Exposures COVID-19
Ocugen Stock Looks Poised to Take a Tumble Right Here
After WHO granted Covaxin a limited Emergency Use Listing, many institutions and hedge funds are likely to sell or short OCGN stock. 
Via InvestorPlace
Exposures COVID-19 Product Safety
Is Ocugen a Buy?
It'll take more than regulatory approvals of its vaccine for it to become a good investment. 
Via The Motley Fool
Exposures COVID-19
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
Ocugen Seeks FDA Emergency Use Nod For Covaxin COVID-19 Vaccine In Kids
Ocugen Inc (NASDAQ: OCGN) said that it sent a request to the FDA for an emergency authorization for its COVID-19 vaccine candidate BBV152, known as Covaxin outside... 
Via Benzinga
Exposures COVID-19 Product Safety
With Ocugen Stock: Follow The Lead of Traders and ‘Sell The News’
WHO approval for Covaxin doesn't change the game much for OCGN stock, steer clear as it slides back to lower prices. 
Via InvestorPlace
Exposures COVID-19
Here's Why Shares of Moderna, Novavax, and Ocugen Have All Been Extremely Volatile This Week
Multiple earnings reports and regulatory updates shook up the coronavirus vaccine space this week. 
Via The Motley Fool
Exposures COVID-19
The Daily Biotech Pulse: NRx's Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus NRx's COVID-19 Drug Fails to Get Authorization From FDA Due To... 
Via Benzinga
Exposures COVID-19 Product Safety
This Surprising FDA Announcement Could Be Huge for Ocugen
The agency will allow vaccine boosters to be mixed and matched. 
Via The Motley Fool
Exposures Product Safety
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
34 35 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.